Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company’s equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
2023-02-14 3:38 pm Sale | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Avidity Partners Management LP | 1,888,887 4% | -316,800 (-14.36%) | View |
2023-02-13 5:57 pm Sale | 13G | ALPINE IMMUNE SCIENCES INC ALPN | BIOTECHNOLOGY VALUE FUND L P | 1,353,815 2.9% | -235,680 (-14.83%) | View |
2023-02-13 4:46 pm Unchanged | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Omega Fund VI L.P. | 2,415,050 5.2% | 0 (Unchanged) | View |
2022-10-03 5:16 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Paradigm Biocapital Advisors LP | 2,214,722 5.03% | 2,214,722 (New Position) | View |
2022-10-03 4:30 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | RA CAPITAL MANAGEMENT L.P. | 4,356,632 9.91% | 4,356,632 (New Position) | View |
2022-09-30 09:37 am Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | GREAT POINT PARTNERS LLC | 3,448,521 7.85% | 3,448,521 (New Position) | View |
2022-09-27 5:02 pm Purchase | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Alpine ImmunoSciences L.P. | 3,905,590 8.6% | 237,292 (+6.47%) | View |
2022-09-27 4:29 pm Sale | 13D | ALPINE IMMUNE SCIENCES INC ALPN | ORBIMED ADVISORS LLC | 4,081,592 9.3% | -145,251 (-3.44%) | View |
2022-09-27 4:00 pm Purchase | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Decheng Capital China Life Sciences USD Fund III L.P. | 7,974,207 17.6% | 2,010,246 (+33.71%) | View |
2022-04-22 4:26 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Lynx1 Capital Management LP | 1,537,345 5.1% | 1,537,345 (New Position) | View |
2022-02-15 2:18 pm Sale | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Frazier Life Sciences VIII L.P. | 3,164,108 10.8% | -13,734 (-0.43%) | View |
2022-02-14 3:21 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Omega Fund VI L.P. | 2,415,050 8.2% | 2,415,050 (New Position) | View |
2022-02-14 1:15 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | BIOTECHNOLOGY VALUE FUND L P | 1,589,495 5.4% | 451,731 (+39.70%) | View |
2022-02-14 11:53 am Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Decheng Capital Management III (Cayman) LLC | 4,708,288 16.11% | 4,708,288 (New Position) | View |
2022-02-11 8:18 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Avidity Partners Management LP | 2,205,687 7.3% | 735,297 (+50.01%) | View |
2021-11-12 5:05 pm Purchase | 13D | ALPINE IMMUNE SCIENCES INC ALPN | ORBIMED ADVISORS LLC | 4,226,843 14.4% | 1,010,637 (+31.42%) | View |
2021-09-21 5:04 pm Purchase | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Decheng Capital China Life Sciences USD Fund III L.P. | 5,963,961 19.6% | 1,554,240 (+35.25%) | View |
2021-09-21 5:03 pm Sale | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Alpine ImmunoSciences L.P. | 3,668,298 12.2% | -544,310 (-12.92%) | View |
2021-09-21 3:37 pm Purchase | 13D | ALPINE IMMUNE SCIENCES INC ALPN | Frazier Life Sciences VIII L.P. | 3,177,842 10% | 440,741 (+16.10%) | View |
2021-02-16 4:46 pm Purchase | 13G | ALPINE IMMUNE SCIENCES INC ALPN | Avidity Partners Management LP | 1,470,390 6.2% | 132,977 (+9.94%) | View |